Repligen CORP Form 4 insider transactions

Repligen's CEO, Olivier Loeillot, reports the acquisition of restricted stock units and stock options, according to a Form 4 filing with the SEC.

Repligen CFO Jason K. Garland disposed of 316 shares of common stock on February 27, 2025, to cover tax withholding obligations.

Repligen's CEO, Olivier Loeillot, disposed of 343 shares of common stock on February 27, 2025, to cover tax withholding obligations related to the release of performance stock units.

Chief Operating Officer James Bylund of Repligen Corp reports disposition of shares to cover tax obligations arising from released performance stock units.

Ralf Kuriyel, Senior VP of R&D at Repligen Corp, disposed of 391 shares of common stock on February 27, 2025, to cover tax withholding obligations.

Director Anthony Hunt of Repligen Corp. reports disposition of shares to cover tax obligations arising from the release of performance stock units.

Senior VP of R&D at Repligen Corp, Ralf Kuriyel, disposed of 275 shares to cover tax obligations arising from the release of performance stock units.

James Bylund, Chief Operating Officer of Repligen Corp, sold 543 shares of common stock on February 24, 2025, to cover tax withholding obligations.

Director Anthony Hunt disposed of 2,380 shares of Repligen Corp. to cover tax withholding obligations arising from the release of performance stock units.

Repligen Corp director Anthony Hunt exercised stock options to acquire 11,808 shares of common stock at a price of $33.87 per share.

Repligen director Anthony Hunt acquired and sold shares of the company's common stock on November 21, 2024, under a pre-arranged 10b5-1 trading plan.

Repligen's CFO, Jason Garland, disposed of 367 shares of common stock to cover tax obligations arising from the release of restricted stock units.

Repligen's CEO, Olivier Loeillot, disposed of 861 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Repligen Corporation director Glenn P. Muir exercised stock options for 19,000 shares at a price of $36.29 per share on November 19, 2024.

Director Anthony Hunt exercised stock options and sold shares of Repligen Corp (RGEN) on September 10, 2024, according to a Form 4 filing.

CEO Olivier Loeillot reports the acquisition of restricted stock units and stock options in Repligen Corporation.

Director Anthony Hunt forfeited a portion of his Repligen Corp equity awards, including common stock and stock options, following an amendment to his equity award agreement.

Karen A. Dawes, a director at Repligen Corp, filed an amended Form 4 with the SEC to correct a misreported number of shares beneficially owned, increasing the reported amount by 2,953 shares.

Ralf Kuriyel, Senior VP of R&D at Repligen Corp, reports the acquisition and disposal of company stock and stock options on August 2, 2024.

Ralf Kuriyel, Senior VP of R&D at Repligen Corp, sold 4,465 shares of common stock on August 1, 2024, at a price of $165.67 per share.

Director Glenn P Muir exercised stock options to acquire 5,000 shares of Repligen Corp (RGEN) common stock on August 1, 2024.

Director Martin D Madaus of Repligen Corp [RGEN] reports purchasing additional shares of common stock on June 14, 2024, increasing his beneficial ownership.

Director Nicolas Barthelemy of Repligen Corp (RGEN) purchased 1,200 shares of common stock at $125.45 per share on June 14, 2024.

Repligen's CEO, Anthony Hunt, purchased 2,000 shares of the company's common stock at a price of $124.08 per share on June 14, 2024.

Karen A. Dawes, a director at Repligen Corp, exercised stock options to acquire 2,953 shares of common stock at $67.71 per share on June 14, 2024.

Repligen's CEO, Anthony Hunt, executed multiple sales of common stock on May 21, 2024, under a pre-arranged 10b5-1 trading plan.

Director Martin D. Madaus reported the acquisition of 701 restricted stock units and 1,376 stock options in Repligen Corp on May 16, 2024.

Director Rohin Mhatre acquired 701 restricted stock units and stock options for 1,376 shares of Repligen Corp on May 16, 2024.

Director Margaret Pax reported the acquisition of 701 restricted stock units and 1,376 stock options in Repligen Corp on May 16, 2024.

Director Konstantin Konstantinov reports acquisition of Repligen Corp stock and stock options via restricted stock units and option awards.